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Abstract We have investigated the role of the C-terminal cytoplasmic domain of the human PTH receptor in effector coupling. Following transient 
expression i  COS-1 cells, coupling to both AC and PI-PLC was observed with the full-length receptor. Progressive C-terminal truncations did not 
dissociate activation of the two signalling systems. In stably transfected 293 cells, however, the full-length receptor as well as the majority of truncated 
constructs stimulated AC exclusively but failed to activate PI-PLC. Activation of both signalling systems was again observed following stable 
expression of a severely truncated receptor (R483) in 293 cells. In this case, pertussis toxin was also found to potentiate the cAMP response to 
hPTH-(1-38) significantly, indicating functional coupling of R483 to Gi proteins. Our results uggest that a core region of the human PTH receptor 
(first, second, third intracellular loop) can interact promiscuously with different G proteins and that the C-terminus of the full-length receptor directs 
the receptor towards an interaction with G~. 
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1, Introduction 
PTH is a major regulator of bone and mineral metabolism. 
In its target cells, which are primarily osteoblasts and kidney 
proximal tubule cells, the hormone elicits a multitude of re- 
sponses which are not readily explained solely on the basis of 
its capacity to stimulate AC (see [1,2] for review). Receptors for 
PTH have been cloned from opossum, rat, and human cDNA 
libraries [3-6]. These receptors bind PTH, PTH-related peptide, 
and N-terminal fragments of these hormones with nanomolar 
affinities. Only one PTH receptor gene exists in the mouse, rat, 
and human genome [7] and so far, there is no evidence lbr 
receptor subtypes mediating different physiological effects [5]. 
Importantly, the rat and human receptor activate both 
cAMP and IP production following transient expression in 
COS cells [4,6]. Stimulation of both signal transduction systems 
has also been observed with the structurally related calcitonin 
receptor [8]. Studies presented in abstract form [9] concerning 
the full-length and a truncated opossum PTH receptor (OK-H, 
see Fig. 1) had suggested that regions within the C-terminus of 
the PTH receptor play an important role in the activation of 
PI turnover, whereas they are dispensable for the coupling to 
AC. 
Given these results, we set out to study the coupling specific- 
ity of the full-length uman PTH receptor, which we had re- 
cently cloned from a kidney cDNA library [6], as well as a 
number of receptor constructs truncated in the C-terminal in- 
tracellular tail region. Coupling to AC and PI-PLC was inves- 
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Abbreviations: AC, adenylyl cyclase; Gs and G~, stimulatory and inhib- 
itory G protein of adenytyl cyclase, respectively; Gq, stimulatory G
protein of PI-PLC; IP, inositol phosphate; PI, phosphoinositide; PI-
PLC, phosphoinositide-specific phospholipase C; PTH, parathyroid 
hormone; hPTH, human parathyroid hormone; cPTHrP, chicken para- 
thyroid hormone-related protein; I~X, pertussis toxin; HEPES, 4-(2- 
hydroxyethyl)-piperazineethanesulfonic acid; IBMX, isobutylmeth- 
ylxanthine; TCA, trichloroacetic a id; 293 cells, human embryonic kid- 
ney 293 cell line. 
tigated both in transiently transfected COS cells as well as in 
stably transfected 293 cells. 
2. Materials and methods 
2.1. Construction of truncated PTH receptors 
Construct pR2 is identical to pRezex-2 as described in [6]. It contains 
the full-length cDNA of the human PTH receptor in the pcDNAIneo 
expression vector (Clontec). For the structure of the various truncated 
receptors described in the following, please refer to Fig. 1. 
To obtain pR3, pR2 was cut with XhoI which releases a small se- 
quence between ucleotide 1,832 of the receptor cDNA and a XhoI site 
in the pcDNAIneo polylinker. The vector was then religated, which 
results in a new C-terminus as indicated in Fig. 1. 
All other constructs were generated starting from the receptor cDNA 
cloned into pUCI9 (pUCR2). To obtain pR4, the unique SfiI site at 
nucleotide 1,904 was used to insert a synthetic sequence containing a 
stop-codon which terminates translation after E579. Plasmids pR5-pR8 
were constructed using polymerase chain reaction (PCR). The region 
between the unique SacI and XhoI sites (nucleotides 1,246 and 1,832, 
respectively) of pUCR2 was replaced by different PCR products. As 5' 
primer, oligonucleotide PTRec-3 [6] was used. Different 3' primers were 
designed to place a stop-codon at the desired position followed by a 
Xhol site. Using BamHI and XhoI, the entire receptor coding regions 
were then subcloned into pcDNAlneo. The fragments generated by 
PCR were verified by DNA sequencing. 
2.2. Transfections 
All cells were grown in Dulbecco's modification of Eagles medium 
(DMEM)/Ham's F12 (1 : 1) medium containing t0% fetal calf serum. 
For transient transfections, COS-I cells were seeded in 10 cm plates at 
a density of 40,000 cetls/cm 2.The following day, cultures were trans- 
fected with 20 pg/plate of the receptor constructs or empty vector 
(control) using the diethylaminoethyl (DEAE)-dextran method [10]. 
Three plates per construct were used. After 24 h, cells were reseeded 
into three 24 well plates at a high cell density of= 100,000 cells per well. 
The following day, these plates were assayed in parallel for binding and 
for agonist-induced cAMP and IP formation. 
Stable transfections were carried out using the calcium phosphate 
coprecipitation method [11]. 293 cells were seeded in six well plates at 
a density of 2 x 105 cells per well and transfected the following day with 
10 ,ug/well of the receptor constructs linearized at the SaclI site of the 
pcDNAIneo vector. After 24 h, normal medium was added and the cells 
were left to recover for one day before starting selection for (3418 
resistance. Cell populations resistant to the antibiotic (1,000/.tg/ml of 
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the material provided by Sigma, Buchs) were obtained within two 
weeks, expanded and frozen. Per receptor construct, five independent 
transfections were carried out in parallel wells. Populations howing 
strongest binding and cAMP response to hPTH-(1-38) were selected for 
further experiments. The identity of the expressed receptors in the 
selected cell populations was independently verified using PCR. 
2.3. Binding experiments 
As radioligand, iodinated chick [Tyr36]PTH related peptide-(1 36) 
([Tyr36]cPTHrP-(I-36)) was used (2200 Ci/mmol, Anawa Ag, Wangen) 
and experiments were carried out as described in [6]. Affinities and Bm~ x
values were determined by scatchard analysis. Nonspecific binding was 
below 10% of total binding in all experiments. 
2.4. Measurements of A C and PI-PLC activities 
To measure cAMP production, cells in 24 well plates were prelabelled 
with [3H]adenine (Amersham) at 2-4 pCi/ml for 2 h. Thereafter, cells 
were washed and incubated in HBS containing 1mM IBMX and the 
indicated agonists at 37°C for 15 min. The cells were then extracted 
with 5% ice-cold TCA. [3H]ATP and [3H]cAMP were separated by 
sequential chromatography on Dowex and alumina columns as de- 
scribed in [12]. 
Inositol phosphate formation was measured following prelabelling 
of cells with [3H]inositol (Amersham) for 24 h at 2-4 pCi/ml. Cells were 
then washed and incubated in HBS containing 20 mM Li ÷ and the 
indicated agonists at 37°C for 20 min. The cells were then extracted 
with ice-cold 10 mM formic acid and samples were processed as de- 
scribed in [13]. Total inositol phosphates were collected. 
Pretreatments with PTX (Sigma, 100 ng/ml) were carried out for 4 h 
prior to agonist application. Both for cAMP and IP formation, data 
are presented as means _+ S.E.M. for duplicate or triplicate determina- 
tions. 
3. Results 
3.1. Truncations at the C-terminus of the human PTH receptor 
do not change binding affinities and do not abrogate coupling 
to both AC and P1-PLC in COS-1 cells 
A series of receptor cDNAs truncated at the C-terminus were 
constructed (Fig. 1) and transiently expressed in COS-1 cells as 
described in section 2. The transfected cells were assayed for 
PTH binding and/or PTH-stimulated cAMP and IP formation. 
With the exception of the shortest construct (pR8), all were 
functionally expressed. The receptor encoded by pR8 lacks a 
number of charged amino acids (E469, K471, K472), which we 
anticipated to be important for the correct positioning of trans- 
membrane domain seven (TM7) in the membrane. All other 
truncated receptors howed binding affinities which were not 
significantly different from the full-length receptor (Fig. 2). 
Likewise, all receptors were still able to stimulate both cAMP 
and IP formation, as is summarized in Table I. Thus, based on 
transient expression in COS cells, no significant changes in 
binding or coupling properties between the full-length and 
functionally expressed truncated receptors became apparent. 
It should be pointed out that the stimulation of PI-PLC 
induced by the PTH receptor is relatively weak. In general we 
observed a less than two-fold increase over basal IP levels 
(Table 1), but when we transfected the hamster 5-HT2A receptor 
[14] into COS-I cells under identical experimental conditions, 
we observed an 8-fold increase with serotonin (not shown). 
3.2. The fit~l-length uman PTH receptor stably expressed in 
293 cells activates Gs only, whereas a severely truncated 
receptor activates G s, Gq and Gi 
Working with UMR 10(:~06 and ROS 17-2.8 osteosarcoma 
cells as well as with secondary cultures of rat and human os- 
teoblasts, we had been unable in the past to detect a significant 
stimulation of PI turnover by PTH peptides, whereas formation 
of cAMP was clearly observed (unpublished results). We were 
therefore interested to determine whether the full-length PTH 
receptor as well as the truncated receptor constructs were able 
to show dual coupling to both AC and PI-PLC also in stably 
transfected cells. 293 cells were transfected with the different 
receptor constructs and G418 resistant cell populations were 
isolated. No subcloning was undertaken in order to avoid ar- 
tefacts due to clonal selection. At least two independently trans- 
fected populations per construct were tested for PTH-induced 
cAMP and IP formation. As in COS cells, pR8 was not ex- 
pressed as a ligand-binding, functional protein. All other cell 
populations tested showed a strong cAMP response to hPTH- 
(1-38), as shown for instance in Fig. 3A for the full-length 
receptor. However, neither cells expressing the latter receptor 
(Fig. 3B) nor cells expressing constructs pR3, pR5 or pR6 (not 
shown) showed a significant PTH response in PI assays, 
whereas a strong stimulation of the system was detectable with 
carbachol, which activates endogenous m3-muscarinic recep- 
tors in 293 cells [8]. 
We were surprised, therefore, to find that cells expressing 
pR7 stimulated IP formation strongly in response to hPTH-(1- 
38) (Fig. 4B) in all experiments carried out. We set out to 
compare second messenger formation stimulated by the wild 
type receptor and by R483 in more detail, using the cell popu- 
lations designated 293 p5 and 293 pR7 pl,  respectively. These 
experiments are summarized in Table 2. The two cell popula- 
tions were found to express a comparable mean number of 
receptors per cell showing similar binding affinities for our 
radioligand. Also, activation of AC by hPTH-(1-38) occured 
with similar ECsos (0.39 and 0.12 nM, respectively). Whereas 
no stimulation of IP formation was detected in the cells express- 
ing the full-length receptor, it occured in the cells expressing 
R483 with an ECs0 of 10 nM. The activation of PI turnover was 
only minimally sensitive to PTX (Fig. 4B), suggesting activation 
of Gq proteins by the truncated receptor. It is important o 
underscore that the activation of PI turnover observed in 293 
pR7 pl cells can not be attributed to higher levels of receptor 
expression compared to 293 p5 (Table 2). 
Table 1 
AC and PI-PLC responses to hPTH-(1-38) in COS-I cells transfected transiently with different receptor constructs 
Receptor construct cAMP Formation IP Formation 
Max. stimulation pECs0 n Max. stimulation pECs0 n 
(% of control) (-log(M)) (% of control) (-log(M)) 
pR2 (full length) 558 _+ 96 
pR5 265 _+ 4 
pR6 209_+ 12 
pR7 410 _+ 106 
9.33 + 0.10 6 198 + 23 8.26 + 0.13 5 
9.03 + 0.29 2 163 + 15 8.03 + 0.33 2 
8.7 + 0.14 2 140 + 21 7.85 + 0.35 2 
9.1 +0.11 3 176_+ 3 8.1 _+0.32 3 
Data are given as means + S.E.M.; n = number of independent experiments. 
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In an attempt to determine whether the receptor encoded by 
pR7 activated other G proteins as well, we checked whether 
PTX was able to potentiate the cAMP response to hPTH-(1- 
38), which would be indicative of an activation of Gi [15]. 
Indeed, following pretreatment of cells with PTX, a signifi- 
cantly stronger cAMP response was observed in 293 pR7 pl at 
high concentrations of agonist (Fig. 4A), whereas no such effect 
was observed in the cells expressing the full-length receptor 
(Fig. 3A). The potentiating action of PTX in 293 pR7 pl was 
specific for the PTH- response, as the toxin did not affect the 
response licited by the fl-adrenergic agonist isoproterenol r 
by forskolin. As expected, PTX reversed the inhibitory effect 
of the Gcactivator aluminum fluoride in both cell systems, 
which demonstrates functionality of the toxin. Stimulation 
of the PTH-response by PTX in the cells expressing R483 
was readily reproducible (increase to 139 + 5% of control at 
TM 7 




Fig. 1. Amino acid sequence ofthe C-terminal cytoplasmic domain of 
the human PTH receptor. Sites of truncation are marked. In the case 
of construct pR3, the cloning procedure results in a new C terminus 
which is not present in the full-length receptor (boxed residues, ee 
methods section). 'OK-H' refers to the truncated receptor described in
[3] which was isolated from opossum kidney cells. This receptor is 
truncated at a site corresponding to R511 of the human receptor. 
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Fig. 2. Ligand binding in COS-I cells transiently transfected with differ- 
ent receptor constructs. Construct pR2 codes for the full-length recep- 
tor. The slope of the lines used to fit the scatchard ata corresponds 
to a dissociation constant of 0.9 nM in all cases. 
10-SM hPTH-(1-38); mean + S.E.M., n = 7). This is a relevant 
effect, as inhibition of stimulated cAMP formation by mainly 
Gr coupled receptors rarely exceeds 50% in comparable experi- 
mental settings [16,17]. The small inhibition of PTH-stimulated 
IP- formation by PTX (Fig. 4B) in 293 pR7 pl is also in 
agreement with an activation of Gi proteins which may stimu- 
late the activity of isoforms of PI-PLC through the release of 
G protein fit subunits [18]. 
There was no evidence for a basal activity of the unliganded 
receptors. Cells expressing pR7, like untransfected cells or cells 
expressing the full-length receptor, showed only minimal in- 
creases of cAMP or IPs following addition of IBMX or lithium 
alone, respectively. 
4. Discussion 
How PTH elicits its diverse physiological effects in target 
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Fig. 3. Stimulation of cAMP (A) and IP formation (B) by hPTH-(1-38) 
and other agonists in 293 cells expressing the full-length receptor (293 
p5 cell population). Cells were pretreated (black symbols and bars) or 
not (open symbols and bars) with PTX prior to the experiment. Fors- 
kolin (FSK), isoproterenol (ISO), and carbachol (CCH) were used at 
10 -5, 10 -5, and 10 -4 M, respectively. To stimulate with aluminum fluo- 
ride (AIF), 10 -5 M A13+ and 5 mM F- were added. 
cells is a matter of debate. There is a general consensus that the 
hormone stimulates cAMP formation, but in addition, several 
laboratories reported activation of P! turnover, PKC or cal- 
cium mobilization [1, 19-23]. The latter signal has been pro- 
posed to arise independently of the formation of IP 3 [24], and 
studies carried out in our hands are in agreement with this 
notion (K. Seuwen and H. Boddeke, manuscript in prepara- 
tion). 
Obviously, our experiments carried out with stably trans- 
fected 293 cells do not support he notion that the full-length 
human PTH receptor activates PI turnover significantly under 
physiological conditions. These data confirm results obtained 
before in our laboratory with ROS 17/2.8 and UMR106 06 
osteosarcoma cells as well as with secondary cultures of human 
and rat osteoblasts. In none of these cultures were we able to 
detect a significant inositol phosphate formation in response to 
PTH peptides (unpublished results). To our knowledge, there 
are no reports which have so far demonstrated activation of PI 
turnover by PTH in cells stably transfected with one of the PTH 
receptors cloned. A recent study on LLC-PKI cells transfected 
with the rat receptor dealt with calcium signals [25]. 
Yet, expression of the full-length PTH receptor in COS cells 
can lead to PTH- induced IP formation, as demonstrated in this 
study and before [4,6]. However, the amplitude of this response 
is small compared to the one observed with other mainly PI- 
coupled receptors (5HT2A receptors, for instance) and requires 
higher agonist concentrations than cAMP formation. The high 
levels of receptor expression achieved in COS cells may lead to 
unspecific oupling and we attribute the weak signal seen in 
these cells to such an effect. In fact, estimating a transfection 
efficiency of 30%, we calculate from our COS cell binding data 
that the transfected cells express > 106 receptors, which is ten 
times more than the 293 cells. Also, in transient expression 
experiments, COS-7 cells have been shown to be a much more 
permissive system than 293 cells to demonstrate coupling to PI 
turnover of a2-adrenergic receptors [26]. 
Our data obtained with the severely truncated receptor R483 
stably expressed in 293 cells are particularly interesting. Not 
only was this receptor functional as an activator of AC, but it 
also stimulated IP formation and a PTX- induced potentiation 
of the cAMP response was observed, thus suggesting coupling 
to Gs, Gq and Gi proteins. Coupling of one receptor to two 
different signal transduction pathways has been described in 
several cases, examples include coupling to G~ and Gq of the 
c~2-adrenergic receptor [16] and to G~ and Gq by the calcitonin 
receptor [8]. Activation of Gs and Gi could be demonstrated 
with chimeras offl2- and a2-adrenergic receptors [15]. However, 
to our knowledge there is only one example of a receptor where 
evidence for promiscous coupling to all three G proteins has 
been obtained. This is the case for the prostaglandin EP3 recep- 
tor subtype, where splice variants of the C-terminal cytoplasmic 
tail exist which engender coupling to Gs or G~ or GJGi/Gq, 
respectively [27]. In this case, however, the receptor variant 
with the shortest cytoplasmic tail shows the highest degree of 
coupling specificity, interacting exclusively with Gs. 
As far as the PTH receptor is concerned, our data indicate 
that sequences within the receptor C terminus direct the recep- 
tor towards an interaction with Gs. Splice variants of the PTH 
Table 2 
Ligand binding and activation of second messenger systems in 293 cells 
stably transfected with the full-length uman PTH receptor cDNA 
(pR2 construct, 293 p5 cell population) and with a truncated receptor 
(pR7 construct, 293 pR7pl) 
Cell type 
293 p5 293 pR7 pl 
(full length R.) (R483) 
Binding sites per cell 155 + 44 45.8 + 5.3 
(× 1,000) (n = 4) (n = 3) 
Affinity for radioligand 6.4 + 0.9 6.9 + 0.6 
(x 10 1,, M) (n = 4) (n = 3) 
pECso 9.41 + 0.09 9.92 + 0.10 
cAMP Formation (n = 8) (n = 7) 
(-log(M)) 
pECs0 no response 8.11 + 0.05 
IP Formation detected (n = 6) 
(-log(M)) 
Binding affinities and number of sites per cell were determined by 
scatchard analysis using iodinated [Tyr36]cPTHrP-(1-36) as ligand. 
Data are given as means + S.E.M.; n = number of independent experi- 
ments. 
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Fig. 4. Stimulation of cAMP (A) and IP formation (B) by hPTH-(1-38) 
and other agonists in 293 cells expressing R483 (293 pR7 pl cell popu- 
lation). Cells were pretreated (black symbols and bars) or not (open 
symbols and bars) with PTX prior to the experiment. Agonists were 
applied as described in the legend to Fig. 3. 
receptor seem to exist in tissues other than bone [28] and it may 
turn out that some of them show coupling to several signalling 
systems. Also, it can not be excluded that unknown mecha- 
nisms acting on the receptor C-terminus modulate coupling in 
a specific cellular setting. 
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